Clinical Trial Update: A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ipatasertib with atezolizumab and paclitaxel in locally advanced or metastatic triple-negative breast cancer has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• PACLITAXEL (PACLITAXEL)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Triple-Negative Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-03-27